STOCKHOLM, SE / ACCESS Newswire / September 15, 2025 / Vicore Pharma Holding AB (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced participation at Pareto Securities' 16th Annual Healthcare Conference 2025:
Location: Stockholm, Sweden
Format: Presentation and 1×1 meetings
Presentation Date and Time: Tuesday, September 16 at 3:45 PM CEST
Participants: Hans Jeppsson, CFO, and Bertil Lindmark, CMO
The company's management will also be available for meetings at the conference.
More information about the event can be found on Pareto's webpage:
https://paretosec.com/updates/events-and-conferences
For further information, please contact:
Megan Richards, VP of IR, Communications, and Portfolio Strategy, tel: +1 978 269-4372, megan.richards@vicorepharma.com
Hans Jeppsson, CFO, tel: +46 70 553 14 65, hans.jeppsson@vicorepharma.com
About Vicore Pharma
Vicore Pharma Holding AB is a clinical-stage pharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company's lead program, buloxibutid (C21), is a first-in-class oral small molecule angiotensin II type 2 (AT2) receptor agonist, which has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA) and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF.
The company is publicly listed on the Nasdaq Stockholm exchange (VICO). www.vicorepharma.com
Attachments
Vicore to Present at Pareto Securities’ 16th Annual Healthcare Conference
SOURCE: Vicore Pharma Holding
View the original press release on ACCESS Newswire
